Cargando…
Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence
AIMS: To evaluate the efficacy of repeated bevacizumab injection in rotational conjunctival flap surgery versus rotational conjunctival flap with adjunctive mitomycin C (MMC) or rotational conjunctival flap alone. MATERIALS AND METHODS: Ninety eyes of 90 patients who underwent primary pterygium surg...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064213/ https://www.ncbi.nlm.nih.gov/pubmed/24178405 http://dx.doi.org/10.4103/0301-4738.120220 |
_version_ | 1782321919158124544 |
---|---|
author | Ozsutcu, Mustafa Ayintap, Emre Akkan, Julide C U Koytak, Arif Aras, Cengiz |
author_facet | Ozsutcu, Mustafa Ayintap, Emre Akkan, Julide C U Koytak, Arif Aras, Cengiz |
author_sort | Ozsutcu, Mustafa |
collection | PubMed |
description | AIMS: To evaluate the efficacy of repeated bevacizumab injection in rotational conjunctival flap surgery versus rotational conjunctival flap with adjunctive mitomycin C (MMC) or rotational conjunctival flap alone. MATERIALS AND METHODS: Ninety eyes of 90 patients who underwent primary pterygium surgery with rotational flap were evaluated. Patients were randomly assigned to undergo conjunctival rotational flap alone (Group A) or conjunctival rotational flap with either 0.02% MMC application (Group B) or adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C). Each group consisted of 30 eyes. Recurrence rates at 9 months were evaluated. RESULTS: There were no statistically significant differences in mean size of the pterygium across the limbus in terms of length (P > 0.5). The recurrence rates at 9 months were 26.6% (n = 8) in Group A, 13.3% (n = 4) in Group B, and 10% (n = 3) in Group C. The recurrence rates in Group B and C were significantly lower than in Group A (P =0.1806). The recurrence rates were similar in Group B and C (P > 0.05). CONCLUSIONS: Subconjunctival bevacizumab injection may decrease the recurrence rate of primary pterygium surgery with rotational conjunctival flap. Further studies with a larger population and longer follow-up period are needed to supplement this study. |
format | Online Article Text |
id | pubmed-4064213 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-40642132014-06-25 Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence Ozsutcu, Mustafa Ayintap, Emre Akkan, Julide C U Koytak, Arif Aras, Cengiz Indian J Ophthalmol Original Article AIMS: To evaluate the efficacy of repeated bevacizumab injection in rotational conjunctival flap surgery versus rotational conjunctival flap with adjunctive mitomycin C (MMC) or rotational conjunctival flap alone. MATERIALS AND METHODS: Ninety eyes of 90 patients who underwent primary pterygium surgery with rotational flap were evaluated. Patients were randomly assigned to undergo conjunctival rotational flap alone (Group A) or conjunctival rotational flap with either 0.02% MMC application (Group B) or adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C). Each group consisted of 30 eyes. Recurrence rates at 9 months were evaluated. RESULTS: There were no statistically significant differences in mean size of the pterygium across the limbus in terms of length (P > 0.5). The recurrence rates at 9 months were 26.6% (n = 8) in Group A, 13.3% (n = 4) in Group B, and 10% (n = 3) in Group C. The recurrence rates in Group B and C were significantly lower than in Group A (P =0.1806). The recurrence rates were similar in Group B and C (P > 0.05). CONCLUSIONS: Subconjunctival bevacizumab injection may decrease the recurrence rate of primary pterygium surgery with rotational conjunctival flap. Further studies with a larger population and longer follow-up period are needed to supplement this study. Medknow Publications & Media Pvt Ltd 2014-04 /pmc/articles/PMC4064213/ /pubmed/24178405 http://dx.doi.org/10.4103/0301-4738.120220 Text en Copyright: © Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ozsutcu, Mustafa Ayintap, Emre Akkan, Julide C U Koytak, Arif Aras, Cengiz Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence |
title | Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence |
title_full | Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence |
title_fullStr | Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence |
title_full_unstemmed | Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence |
title_short | Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence |
title_sort | repeated bevacizumab injections versus mitomycin c in rotational conjunctival flap for prevention of pterygium recurrence |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064213/ https://www.ncbi.nlm.nih.gov/pubmed/24178405 http://dx.doi.org/10.4103/0301-4738.120220 |
work_keys_str_mv | AT ozsutcumustafa repeatedbevacizumabinjectionsversusmitomycincinrotationalconjunctivalflapforpreventionofpterygiumrecurrence AT ayintapemre repeatedbevacizumabinjectionsversusmitomycincinrotationalconjunctivalflapforpreventionofpterygiumrecurrence AT akkanjulidecu repeatedbevacizumabinjectionsversusmitomycincinrotationalconjunctivalflapforpreventionofpterygiumrecurrence AT koytakarif repeatedbevacizumabinjectionsversusmitomycincinrotationalconjunctivalflapforpreventionofpterygiumrecurrence AT arascengiz repeatedbevacizumabinjectionsversusmitomycincinrotationalconjunctivalflapforpreventionofpterygiumrecurrence |